Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.2B 6.63B 6.2B 11.63B 773B 11.84B 79.54B 30.81B 381B 30.76B 30.09B 1,324B | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.58B 6.07B 5.67B 10.64B 707B 10.83B 72.79B 28.19B 349B 28.15B 27.53B 1,212B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 12.5 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Reents
PSD | President | 59 | 31/07/2024 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
Scott Reents
BRD | Director/Board Member | 59 | 31/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 31/07/24 | Bain Capital Private Equity LP
| Issuer sale | Company | 65,679,781 | 36.0492% | |
| 31/07/24 | Issuer sale | Director | 93,932 | 0.0516% | ||
| 31/07/24 | Bain Capital Private Equity LP
| Issuer sale | Company | 65,679,781 | 36.0492% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +38.94% | 8.19B | |
| +4.43% | +2.49% | +61.83% | +115.25% | 52.88B | |
| +1.58% | +19.37% | +75.37% | +85.18% | 50.98B | |
| -0.23% | -0.98% | -14.12% | -16.00% | 22.81B | |
| +0.98% | +9.05% | -0.36% | +423.40% | 22.43B | |
| +2.03% | +7.40% | +28.79% | -12.32% | 17.01B | |
| +0.88% | +5.78% | +30.82% | -34.26% | 15.91B | |
| +0.68% | +2.54% | +22.28% | +168.03% | 13.29B | |
| +3.02% | +12.74% | +143.33% | +308.04% | 13.58B | |
| +0.79% | +1.59% | +85.06% | +116.18% | 11.75B | |
| Average | +1.49% | +5.31% | +43.30% | +119.24% | 22.88B | |
| Weighted average by Cap. | +1.95% | +6.31% | +48.09% | +117.61% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -309M -284M -266M -499M -33.17B -508M -3.41B -1.32B -16.35B -1.32B -1.29B -56.82B | -433M -380M -350M -328M -614M -40.84B -626M -4.2B -1.63B -20.13B -1.63B -1.59B -69.97B |
| Net Debt | -523M -460M -423M -396M -743M -49.37B -756M -5.08B -1.97B -24.34B -1.96B -1.92B -84.58B | -695M -611M -563M -526M -987M -65.62B -1.01B -6.75B -2.62B -32.35B -2.61B -2.55B -112B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
